Castle Biosciences, Inc. (CSTL) vs Lumexa Imaging Holdings, Inc. Common Stock (LMRI)
A side-by-side comparison of Castle Biosciences, Inc. and Lumexa Imaging Holdings, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CSTL
Castle Biosciences, Inc.
$33.69HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
LMRI
Lumexa Imaging Holdings, Inc. Common Stock
$10.67HealthcareDelayed quote: Oct 6, 2026, 12:49 PM EDT
Total return — CSTL vs LMRI
growth of $100 · dividends reinvested · last 1yCSTL -3.6% (-3.6%/yr)LMRI -41.8% (-41.8%/yr)CSTL compounded faster over this window
CSTL LMRI
CSTL vs LMRI: by the numbers
- •CSTL is the larger company ($1.03B vs $1.03B market cap).
- •Both run net losses; LMRI's is the smaller (-2.66% vs -5.43% net margin).
Metrics side by side
Valuation
| Metric | CSTL | LMRI |
|---|---|---|
| Forward P/E | N/A | 16.62 |
| P/S ratio | 2.88 | 0.98 |
| P/B ratio | 2.19 | 1.67 |
| EV / EBITDA | N/A | 28.01 |
| FCF yield | N/A | 3.11% |
Profitability
| Metric | CSTL | LMRI |
|---|---|---|
| Gross margin | 77.26% | 11.80% |
| Operating margin | -8.99% | 1.38% |
| Net margin | -5.43% | -2.66% |
| ROE | -4.13% | -4.51% |
| ROIC | -6.33% | 0.86% |
Growth (annualized)
| Metric | CSTL | LMRI |
|---|---|---|
| Revenue CAGR (5Y) | 35.55% | N/A |
| Total return CAGR (5Y) | -10.28% | N/A |
Go deeper
Dig into the metrics
Castle Biosciences ROELumexa Imaging Holdings, Inc. Common Stock ROECastle Biosciences operating marginLumexa Imaging Holdings, Inc. Common Stock operating marginCastle Biosciences revenue growthLumexa Imaging Holdings, Inc. Common Stock revenue growthCastle Biosciences free cash flowLumexa Imaging Holdings, Inc. Common Stock free cash flow
Castle Biosciences & Lumexa Imaging Holdings, Inc. Common Stock appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.